Tripelennamine
As of the edition of 20 October 2026, Tripelennamine is a small molecule: marketed, first approved in 1982 (US); acts on HRH1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Pbz
- First approved
- 1 January 1982 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Perrigo Espana S.A.; 2 holders in all
- Registered trials
- 1, 0 stopped early
- Disease areas
- Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Acquired holder | 2003 to now |
| GEIGY Pharmaceuticals | Earlier holder |